Companies reported varied funding and expansion activities, with Medpal AI raising further capital via its ATM facility to boost its online pharmaceutical subsidiary, and Yellow Cake PLC proposing a new share placing to fund a strategic uranium acquisition. Strategic shifts were also in focus, as Pennpetro Energy works towards audit completion and a potential Reverse Take Over while seeking to resume trading, Oxford Biomedica extended its deadline for a potential EQT cash offer, and Synthomer confirmed exploring debt refinancing options to reduce leverage. Meanwhile, Maintel Holdings saw a governance requisition withdrawn, albeit with further action expected, contrasting with Raspberry Pi Holdings where the CEO made a significant share purchase, demonstrating strong insider confidence post-listing.
Energy company Pennpetro Energy PPP provided an update, noting that its auditors expect to finalise the 2024/25 accounts audit by February 20, 2026. Following this, the company intends to publish its financial results and seek a return to trading for its shares on the London Stock Exchange. The company is also evaluating a proposed Reverse Take Over, which could influence the timeline for its shares to resume trading.
Medpal AI MPAL, a UK-based digital health and artificial intelligence company, announced it has secured an additional £467,640 through its At-The-Market equity issuance facility. This latest tranche brings the total capital raised via the facility to £1,684,295. The funds will be allocated to MedPal AI's online pharmaceutical subsidiary, MedPal Limited, to enhance inventory, broaden its product offerings, and launch marketing campaigns for its pharmacy and clinic divisions.
Yellow Cake YCA, a specialist company in the uranium sector, unveiled plans for a proposed purchase of uranium, to be financed through a placing of new ordinary shares. This strategic initiative aims to bolster the company's physical uranium reserves, reinforcing its market presence. The capital raise and subsequent acquisition are pivotal to its long-term strategy in the uranium market.
Raspberry Pi Holdings RPI reported that its Chief Executive Officer, Eben Upton, acquired additional Ordinary Shares in the company. Following this transaction, Mr. Upton's total shareholding increased to 2,586,452 shares. This move by a senior executive typically indicates a belief in the company's future performance and value.
Maintel Holdings MAI confirmed that Oryx International Growth Fund Limited has withdrawn its requisition for a general meeting, which had sought to remove Stephen Beynon as chairman and appoint Martin Rowland. Despite the withdrawal, Oryx expressed its intent to submit another requisition following the release of Maintel's annual results for the year ended 31 December 2025. This development suggests continuing shareholder activism regarding the company's leadership.
Oxford Biomedica OXB, the gene therapy company, confirmed an extension to the "put up or shut up" deadline for EQT to announce a firm intention to make an offer. The new deadline for the possible cash offer is 5:00 p.m. on March 10, 2026. This decision reflects ongoing preliminary discussions between the Board of Oxford Biomedica and EQT regarding a potential acquisition.
Chemicals company Synthomer SYNT has addressed recent media speculation, confirming that it is in discussions with lenders to refinance its debt facilities maturing in the second half of 2027. The company is evaluating a range of options to reduce its leverage and support its speciality chemicals strategy, which includes considering the possibility of raising additional capital. No firm decisions have been made regarding the terms or timing of any potential financing.